グラウコマのリスクに対する肥満や体重過剰の影響:メタ解析
Piao Xie1, Hanze Qiu2, Luyu Zhao3
1Department of Ophthalmology, The First Affiliated Hospital of Jinan University, Jinan University, Guangzhou, China.
Frontiers in medicine
|February 16, 2026
まとめ
肥満と体重過剰は,特に先進国や男性において,緑内障のリスクを大幅に高めます. 健康的な体重を維持することは,グラウコマによる視力喪失を予防するために重要であるかもしれません.
科学分野:
- オフタルモロジック (眼科)
- 公衆衛生は公衆衛生である.
- メタボリック障害 メタボリック障害
背景:
- グラウコマは,全世界で不可逆的な失明の主要な原因です.
- 肥満/肥満と緑内障の発症の関連性は議論されている.
- グラウコマの予防は,公衆衛生上の重要な懸念事項である.
研究 の 目的:
- 肥満または体重過剰と緑内障を発症するリスクとの関連を調べる.
- この関係に関する既存の研究からの証拠を合成する.
主な方法:
- PubMed,Embase,Web of Scienceのデータベースから体系的な文献検索を行いました.
- 肥満/過体重および緑内障のリスクに関するオリジナルの研究の含有.
- 95%信頼区間 (CI) のオッズ比率 (OR) とハザード比率 (HR) を用いた臨床結果の評価.
主要な成果:
- 分析には13件の研究が含まれていた.
- 肥満/過体重は,グラウコマのリスクが60%増加した (OR: 1.60 [95%CI: 1.19-2.17]).
- より高いリスクは,先進国 (OR: 1.91) と男性 (OR: 2.14) で観察されました.
結論:
- 肥満と過体重は,特にオッズ比率の値に基づいて,緑内障のリスクを高めるようです.
- 先進国の個人や肥満/肥満の男性では,リスクが高くなります.
- 体重管理は,緑内障の予防のための潜在的な戦略です.
関連する概念動画
Glaucoma: Overview
1.4K
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
1.4K
Drug Dosing: Obese Patients
275
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
275
Open Angle Glaucoma: Treatment
1.0K
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
1.0K
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
301
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
301
Obesity
1.4K
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.4K
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
197
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
197


